Suzhou Fushilai Pharmaceutical Co. Ltd. Total Assets
Suzhou Fushilai Pharmaceutical Co. Ltd. total assets. Based on the latest financial reports, Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) holds total assets worth CN¥2.13 Billion CNY (≈ $312.10 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Suzhou Fushilai Pharmaceutical Co. Ltd. market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)
Total assets of Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024. This chart illustrates how Suzhou Fushilai Pharmaceutical Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. See today's stock price for Suzhou Fushilai Pharmaceutical Co. Ltd. for real-time trading data and today's change.
Suzhou Fushilai Pharmaceutical Co. Ltd. - Asset Composition Analysis
Suzhou Fushilai Pharmaceutical Co. Ltd. Total Assets Breakdown (December 2024)
Suzhou Fushilai Pharmaceutical Co. Ltd. total assets breakdown as of December 2024. Suzhou Fushilai Pharmaceutical Co. Ltd.'s total assets of CN¥2.13 Billion consist of 77.2% current assets and 22.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.8% |
| Accounts Receivable | CN¥87.51 Million | 4.2% |
| Inventory | CN¥154.83 Million | 7.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥62.56 Million | 3.0% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Suzhou Fushilai Pharmaceutical Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Suzhou Fushilai Pharmaceutical Co. Ltd. working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Suzhou Fushilai Pharmaceutical Co. Ltd.'s current assets represent 77.2% of total assets in 2024, an increase from 50.7% in 2019.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2024, down from 25.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 7.4% of total assets.
Suzhou Fushilai Pharmaceutical Co. Ltd. Competitors by Total Assets
Key competitors of Suzhou Fushilai Pharmaceutical Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Suzhou Fushilai Pharmaceutical Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.37 | 13.66 | 9.90 |
| Quick Ratio | 9.49 | 12.33 | 9.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.44 Billion | CN¥1.50 Billion | CN¥1.39 Billion |
Suzhou Fushilai Pharmaceutical Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Suzhou Fushilai Pharmaceutical Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.65 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | CN¥2.09 Billion |
| Market Capitalization | $300.48 Million USD |
Valuation Analysis
Below Book Valuation: The market values Suzhou Fushilai Pharmaceutical Co. Ltd.'s assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Suzhou Fushilai Pharmaceutical Co. Ltd.'s assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)
The table below shows the annual total assets of Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.09 Billion ≈ $305.50 Million |
-1.34% |
| 2023-12-31 | CN¥2.12 Billion ≈ $309.65 Million |
+0.84% |
| 2022-12-31 | CN¥2.10 Billion ≈ $307.06 Million |
+116.26% |
| 2021-12-31 | CN¥970.31 Million ≈ $141.99 Million |
+23.10% |
| 2020-12-31 | CN¥788.25 Million ≈ $115.35 Million |
+4.90% |
| 2019-12-31 | CN¥751.44 Million ≈ $109.96 Million |
-- |
About Suzhou Fushilai Pharmaceutical Co. Ltd.
Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and … Read more